Literature DB >> 12986662

Experimental study of physical factors, including fibrin formation, influencing the spread of fluids and small particles within and from the peritoneal cavity of the dog.

H H ZINSSER, A W PRYDE.   

Abstract

Entities:  

Keywords:  PERITONEUM

Mesh:

Substances:

Year:  1952        PMID: 12986662      PMCID: PMC1802146          DOI: 10.1097/00000658-195211000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  5 in total

1.  FIBRINOLYSIS IN GRAM-NEGATIVE BACILLI.

Authors:  H H Zinsser; W J Williams
Journal:  J Bacteriol       Date:  1949-10       Impact factor: 3.490

2.  Influence of antibiotics and sulfonamides of the mortality and bacteria of experimental peritonitis.

Authors:  H A ZINTEL; H H ZINSSER; W RUNYON; G L JACKSON; A C NICHOLAS; M M WILEY; W J WILLIAMS
Journal:  Surg Gynecol Obstet       Date:  1950-12

3.  The Effect of Blood in Experimental Peritonitis.

Authors:  L Rademaker
Journal:  Ann Surg       Date:  1933-03       Impact factor: 12.969

4.  X. Peritoneal and Pleural Absorption, with Reference to Postural Treatment.

Authors:  W E Dandy; L G Rowntree
Journal:  Ann Surg       Date:  1914-04       Impact factor: 12.969

5.  Passage of radioactive erythrocytes from the peritoneal cavity into the blood stream during experimental ascites.

Authors:  F W McKEE; W B STEWART
Journal:  J Exp Med       Date:  1950-06-01       Impact factor: 14.307

  5 in total
  16 in total

Review 1.  Role of fibrin deposition in the pathogenesis of intraabdominal infection.

Authors:  O D Rotstein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

2.  Tissue plasminogen activator reverses the deleterious effect of infection on colonic wound healing.

Authors:  K A Houston; D I McRitchie; O D Rotstein
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

3.  In situ assays demonstrate that interferon-gamma suppresses infection-stimulated hepatic fibrin deposition by promoting fibrinolysis.

Authors:  I K Mullarky; F M Szaba; C G Winchel; M A Parent; L W Kummer; N Mackman; L L Johnson; S T Smiley
Journal:  J Thromb Haemost       Date:  2006-07       Impact factor: 5.824

4.  Adjuvant effect of heparin on peritonitis induced in rats.

Authors:  M M Bagree; R K Aneja
Journal:  Jpn J Surg       Date:  1983-11

5.  Tumor necrosis factor alpha and gamma interferon, but not hemorrhage or pathogen burden, dictate levels of protective fibrin deposition during infection.

Authors:  Isis K Mullarky; Frank M Szaba; Kiera N Berggren; Lawrence W Kummer; Lindsey B Wilhelm; Michelle A Parent; Lawrence L Johnson; Stephen T Smiley
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

6.  Infection-stimulated fibrin deposition controls hemorrhage and limits hepatic bacterial growth during listeriosis.

Authors:  Isis K Mullarky; Frank M Szaba; Kiera N Berggren; Michelle A Parent; Lawrence W Kummer; Wangxue Chen; Lawrence L Johnson; Stephen T Smiley
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

7.  Disparate mechanisms of induction of procoagulant activity by live and inactivated bacteria and viruses.

Authors:  S B Sinclair; O D Rotstein; G A Levy
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot.

Authors:  Krishana C Gulla; Kshitij Gupta; Anders Krarup; Peter Gal; Wilhelm J Schwaeble; Robert B Sim; C David O'Connor; Krishnan Hajela
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

Review 9.  Thrombosis as an intravascular effector of innate immunity.

Authors:  Bernd Engelmann; Steffen Massberg
Journal:  Nat Rev Immunol       Date:  2012-12-07       Impact factor: 53.106

10.  Fibrin in peritonitis. V. Fibrin inhibits phagocytic killing of Escherichia coli by human polymorphonuclear leukocytes.

Authors:  O D Rotstein; T L Pruett; R L Simmons
Journal:  Ann Surg       Date:  1986-04       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.